check_circle_outline Volunteer. Eligibility to volunteer, join ASCO committees, and advocate for cancer care.

6 days ago · Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.

Free access to ASCO publications and discounted meeting registration. Exclusive networking opportunities, with access to ASCO Membership Directory and myConnection. Eligibility to volunteer, join ASCO committees, and advocate for cancer care ...

6 days ago · Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.

Target Population and Audience •Men with noncastrate advanced, recurrent, or metastatic prostate cancer. 7 Target Population Target Audience •Medical oncologists, radiation oncologists, urologists, nurses, other health care

CPT Copyright 2022 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association." 2021 Evaluation and ...

This table is derived from recommendations in Antiemetics: ASCO Guideline Update. This is a tool based on an ASCO guideline and is not intended to substitute for the independent professional judgment of the treating

1 . American Society of Clinical Oncology ® Conquer Cancer ®, the ASCO Foundation . Priority Points Guidelines for the Selection of Exhibit Space and Hotel Accommodations for the 2025 ASCO

AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 Mill Road, Suite 800 n Alexandria, VA 22314 n 571-483-1300 n www.asco.org ©2012 American Society of Clinical Oncology. For permissions information, please contact ASCO at permissions@asco.org.

Summary of Recommendations Recommendation 1.2a For the patient with a cN0 neck, an ipsilateral elective neck dissection should include nodal levels, Ia, Ib, II,